Israel - English - Ministry of Health

inovamed ltd - magnesium sulfate as heptahydrate - solution for injection / concentrate for solution for inj/inf - magnesium sulfate as heptahydrate 500 mg / 1 ml - magnesium sulfate - magnesium sulfate 50%w/v inovamed is indicated for:1. the treatment of magnesium deficiency in hypomagnesaemia. 2. the prevention and treatment of hypomagnesaemia in patients receiving total parenteral nutrition. 3. the control and prevention of seizures in severe pre-eclampsia. 4. the control and prevention of recurrent seizures in eclampsia

Israel - English - Ministry of Health

a.l. medi-market ltd. - magnesium sulfate heptahydrate - solution for injection / concentrate for solution for inj/inf - magnesium sulfate heptahydrate 500 mg / 1 ml - magnesium sulfate - magnesium sulfate kalceks 50% solution for injection or infusion is indicated for: the treatment of magnesium deficiency in hypomagnesaemiathe prevention and treatment of hypomagnesaemia in patients receiving total parenteral nutritionthe control and prevention of seizures in severe pre-eclampsiathe control and prevention of recurrent seizures in eclampsia

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - arsenic trioxide, quantity: 10 mg - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - for the induction of remission and consolidation in patients with acute promyelocytic leukaemia (apl) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression.,for the induction of remission and consolidation in patients with previously untreated acute promyelocytic leukaemia (apl) in combination with all-trans retinoic acid (atra) and/or chemotherapy and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - furosemide, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; nitrogen; sodium chloride - oedema: furosemide ? aft is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. it is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations.,furosemide ? aft injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset of diuresis is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, furosemide ? aft is indicated by the intravenous route. parenteral use should be replaced with oral furosemide as soon as practical.

Ireland - English - HPRA (Health Products Regulatory Authority)

rowa pharmaceuticals limited - magnesium - granules for oral solution - 5 millimole(s) - magnesium aspartate

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

magnesium 97mg (4mmol)) chewable tablets (neoceuticals ltd - magnesium glycerophosphate - chewable tablet - 97.2mg

Ireland - English - HPRA (Health Products Regulatory Authority)

foran healthcare limited, - magnesium sulfate dried - cutaneous paste - 38.5 percent weight/weight - other dermatologicals; magnesium sulfate

Ireland - English - HPRA (Health Products Regulatory Authority)

martindale pharmaceuticals ltd - potassium chloride; procaine hydrochloride; magnesium chloride - concentrate for solution for infusion - 163mg/ml + 60mg/ml+14 milligram(s)/millilitre - potassium chloride, combinations

United States - English - NLM (National Library of Medicine)

select brand dist. - magnesium citrate (unii: rho26o1t9v) (magnesium cation - unii:t6v3lhy838) - magnesium citrate 1.745 g in 29.6 ml - saline laxative - relieves occasional constipation (irregularity) - generally produces bowel movement in 1/2 to 6 hours

United States - English - NLM (National Library of Medicine)

select brand dist. - magnesium citrate (unii: rho26o1t9v) (magnesium cation - unii:t6v3lhy838) - magnesium citrate 1.745 g in 29.6 ml - saline laxative - relieves occasional constipation (irregularity) - generally produces bowel movement in 1/2 to 6 hours